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ABSTRACT
Depression after stroke is common. Although different opinions exist about the
definition, diagnosis, and measurement of outcomes related to depression after stroke,
there is little debate about the prevalence of depression symptoms and their impact on
stroke survivors and their families. Depression after stroke has long been recognized as a
common condition with many negative effects in the poststroke period, but more recently
depression has also been identified as an independent stroke risk factor. Given that there
are at least 500,000 new ischemic strokes yearly in the United States, a conservative
estimate is that 150,000 U.S. stroke survivors develop poststroke depression each year.
Because effective treatments exist but are likely underutilized for depression, this is an
important example of an evidence-practice gap to which increased efforts to improve care
should be made. Such efforts would likely improve not only patient symptoms but may also
decrease stroke risk, influence stroke functional recovery, decrease mortality, and reduce
poststroke health care utilization. This article provides an overview of depression diagnosis
in stroke, reviews the epidemiology of poststroke depression and its associated morbidity
and mortality, and reviews existing evidence on the treatment and prevention of poststroke
depression.
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Objectives: On completion of this article, the reader will have an increased awareness of poststroke depression and the risk factors for
developing post stroke depression.
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Depression after stroke is common. The vast
majority of the literature has studied depression after
ischemic stroke only, not hemorrhagic stroke; therefore,
the term ‘‘poststroke depression’’ (PSD) will be used here
to indicate depression related to ischemic stroke unless
otherwise specified. Although different opinions exist
about the definition, diagnosis, and measurement of
outcomes related to depression after stroke, there is little
debate about the prevalence of depression symptoms and
their impact on stroke survivors and their families. Given
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that there are at least 625,000 new ischemic strokes
yearly in the United States, a conservative estimate is
that at least 185,000 U.S. stroke survivors develop PSD
each year. Because effective treatments exist but are
likely underutilized for depression, this is an important
example of an evidence-practice gap to which increased
efforts to improve care should be made. Such efforts not
only would likely improve patient symptoms but may
also influence stroke functional recovery, decrease mor-
tality, and reduce poststroke health care utilization. This
article provides an overview of depression diagnosis in
stroke, reviews the epidemiology of PSD and its asso-
ciated morbidity and mortality, and reviews existing
evidence on the treatment and prevention of PSD.
DEFINING DEPRESSION
Depression is a syndromic condition that, like many
disorders, is diagnosed and monitored by assessing
symptoms. The most commonly used diagnostic algo-
rithm is based on the Diagnostic and Statistical Manual,
Fourth Version (DSM-IV) and includes criteria for
major depression and minor depression as well as criteria
for other categories of depressive disorders (Table 1).
Diagnosis of major depression requires persistent low
mood or loss of interest in most activities for at least
2 weeks, including some of the following symptoms to
total at least five symptoms: weight change (increase or
decrease), altered sleep pattern (too little or too much),
lack of energy, poor concentration, agitation, reduced
self-esteem, suicidal ideas or plans. Minor depression
requires three or four of these symptoms, with at least
one symptom being depressed mood or loss of interest,
for at least 2 weeks.
PSD is typically defined simply as depression that
develops after ischemic stroke. Most studies of PSD do
not distinguish between major and minor depression
diagnoses. Studies of PSD are also complicated by the
varied time frames used in this definition, the methods
of diagnosing depression, and the different population
of stroke patients studied.1–4 Permeating these meth-
odological difficulties is the theoretical problem of eval-
uating mental functioning in brain-injured patients.
Potential difficulties include evaluating mood in patients
with language, cognitive, and attentional disturbances
and attributing somatic symptoms to mood disorders
when the symptoms may be more strongly related to the
neurological condition.3
Because physical symptoms are a common feature
of the poststroke period and because physical symptoms
like poor sleep and fatigue are part of the diagnostic
assessment of depression yet are also common in non-
depressed patients, some authors have questioned whe-
ther PSD is overdiagnosed in the poststroke period due to
non–depression-related physical complaints. Although
this hypothesis seems reasonable, it has not been convinc-
ingly demonstrated in a stroke cohort. Robinson and
colleagues did not find ‘‘overdiagnosis’’ of PSD with
only 2 to 3% of patients having solely somatic symptoms
of depression,5 and we likewise found that although PSD
patients had more severe physical depression symptoms
after stroke, they did not have a greater number of physical
depression symptoms compared with depressed older
adults without stroke (Fig. 1).6 We also compared symp-
tom endorsement on the Patient Health Questionnaire
(PHQ)-9 items between depressed and nondepressed
patients and found that all symptoms, including sleep,
fatigue, appetite, and feeling slowed down or agitated,
were at least five times more likely to be endorsed by
depressed patients than nondepressed patients.7
Another key question for PSD diagnosis is
how soon after stroke PSD can be reliably diagnosed.
Because depression symptoms, and symptoms in general,
are heightened at times of illness and elevated situational
stressors, persons hospitalized for any condition report
more depressive symptoms than those not hospitalized.
This makes diagnosis of PSD difficult in the immediate
poststroke period. DSM-IV diagnosis requires symp-
toms to be present for at least 2 weeks, so adherence to
a diagnostic rather than a screening algorithm can be
helpful in clarifying this issue. Stroke patients may also
have symptoms like emotional lability or apathy as a
manifestation of frontal stroke and not depression.8 The
relationship between early emotionality and subsequent
depression diagnosis in stroke patients has been
studied,9,10 with most authors reporting some associa-
tion between early emotionality and later depression.
Although not all patients with emotionality meet criteria
for PSD, these symptoms should prompt follow-up
screening after 2 weeks as patients with early emotion-
ality are probably at increased risk for developing PSD.
SCREENING FOR DEPRESSION
AFTER STROKE
Several established depression screening tools have been
validated in stroke cohorts, and at least one tool has been
Table 1 DSM-IV Symptoms of Major Depression
At least one of these:
Depressed mood
Anhedonia
And some of these to total five symptoms present for at least
2 weeks:
Change in appetite/weight (increase or decrease)





Suicidal thoughts or plans





















































developed specifically for depression screening in stroke
survivors.7,11–15 Before evaluating or choosing a partic-
ular tool for use in a stroke population, it is important to
understand some critical differences in screening tools.
Some tools, like the Center for Epidemiology Studies-
Depression (CES-D) and the Beck Depression Inven-
tory, are designed to screen for depression but not to
make a particular diagnosis (e.g., differentiate major
depression from minor or other depression). Other tools,
for example the Zung and the PHQ-9, are designed to
be both a screening tool, with an established cut point to
indicate patients with a high probability of depression
diagnosis, and a diagnostic tool, where not just the
overall score but the specific combination of symptoms
are taken into consideration and validated against a
psychiatric interview to establish diagnostic algorithms
for the scales.
This important principle can be illustrated with
the PHQ-9, a nine-item scale designed for use in out-
patient primary care clinics, which assesses the nine
DSM-IV depression symptom criteria for frequency of
occurrence during the previous 2 weeks. As a screening
tool, the nine items are summed, resulting in a score
ranging from 0 (no depressive symptoms) to 27 (all nine
symptoms occurring daily).16,17 In this use, a PHQ-9
score  10 has been found to have 88% sensitivity and
88% specificity for a diagnosis of major depression. The
first two items of the PHQ-9 assess depressed mood and
anhedonia, and these two items (the PHQ-2) have also
been tested as a depression screening tool in primary care
clinics, with score  3 identified as having 83% sensi-
tivity and 92% specificity for identifying patients with
major depression. As a diagnostic instrument, the PHQ-
9 can be used to identify patients with major depression
if five or more of the nine symptoms have been present
at least more than half the days of the past 2 weeks and if
at least one of these five symptoms endorsed is either
depressed mood or anhedonia. We have recently shown
that the PHQ-9 performs well as a depression screening
tool in stroke patients, with 91% sensitivity and 83%
specificity for major depression and 78% sensitivity and
96% specificity for any depression diagnosis.7 Likewise,
the PHQ-2 performed nearly as well with sensitivity of
83% and specificity of 84% for major depression and
sensitivity 78% and specificity 95% for any depression
diagnosis. The PHQ-2, however, can only be used as a
screening tool, so patients with a score  3 on this scale
should be administered the remaining seven items for
more complete assessment of depression symptoms (in-




Another critical issue that has not been well studied is
the timing of depression in relation to the stroke. Most
commonly, any depression recognized after a stroke has
occurred is termed PSD, and whether the depressive
symptoms predated the stroke is not ascertained. In our
ongoing trial of depression case management versus
usual care in stroke survivors, preliminary data in 180
depressed subjects showed that 30% report being on an
antidepressant at the time their stroke occurred. This is
of interest not only because prior depression has been
identified as a risk factor for the development of PSD but
Figure 1 Comparison of somatic symptom clusters in PSD versus geriatric depression patients. (PHQ-9 Copyright# 1999 Pfizer, Inc.
All rights reserved. Reproduced with permission. PRIME MD TODAY is a trademark of Pfizer, Inc.)





















































also because depression itself is increasingly recognized
as a risk factor for stroke. Despite this conceptual
complexity, for ease of use and convention, most authors
and researchers continue to use the term ‘‘poststroke
depression’’ to refer to any depression present after
stroke, regardless of the timing of symptom onset.
Further research is needed in this area to better under-
stand depressive symptoms as a risk for stroke, and
potential treatment and recovery implications for stroke
survivors with longstanding versus more recent depres-
sive symptoms.
DEPRESSION AS A STROKE
RISK FACTOR
Depression and depressive symptoms have been recog-
nized as a risk factor for cardiovascular disease and, more
recently, as a risk factor for stroke. Although a review of
the epidemiology of depression and other psychiatric
disorders after myocardial infarction (MI) is beyond
the scope of this review, Davies et al have provided a
thorough review of the epidemiology and treatment of
anxiety and depressive disorders in patients with cardi-
ovascular disease.18 Several studies have found a link
specifically between depressive symptoms and increased
risk of stroke (Table 2). In a random sample of 1134
subjects aged 65 and older, prior stroke was associated
with a sixfold increase in 2-year risk of depression, even
when controlling for functional status, stroke risk fac-
tors, and prior depression symptoms.19 Similarly, in a
6-year prospective cohort study of nearly 2500 older
adults, Ostir and colleagues found that stroke risk
increased as scores on the CES-D increased (relative
risk [RR] of stroke 1.04 for each 1-point CES-D
increase) and, conversely, that positive affect scores had
a strong inverse relationship with stroke (RR 0.74).20 In
this sample, the authors also demonstrated that baseline
depressive symptoms were associated with less recovery
in activities of daily living after stroke, MI, or hip
fracture, suggesting that the negative impact of depres-
sion on recovery after an acute event is likely mediated
via multiple physiologic, behavioral, and social mecha-
nisms rather than by an effect on neural plasticity
alone.21 Data from the NHANES study likewise
showed that depression symptoms at baseline were
associated with increased stroke risk during an average
of 16 years of follow-up even after adjusting for demo-
graphic and other vascular risk factors (overall RR of
stroke 1.73, 95% confidence interval [CI]¼ 1.30 to
2.31).22 The relationship was strongest in blacks (RR
of stroke 2.6) and only of borderline significance in white
women (RR¼ 1.52, 95% CI¼ 0.97 to 2.38). This rela-
tionship has also been demonstrated in prospective
cohorts from other countries, including the finding in
a cohort of 901 Japanese adults aged 40 to 78 years that
depressive symptoms increased the 10-year adjusted
risk of subsequent ischemic stroke at least twofold.23
Whether this observed increase in stroke risk is specif-
ically related to depression or is seen with other mental
health disorders is not clear, but one Danish population-
based study demonstrated that stroke risk was increased
22% in older patients previously hospitalized for depres-
sive disorder but not in those hospitalized for mania/
bipolar disorder.24 This relationship between depression
symptoms and stroke does appear to be at least some-
what bidirectional, another factor that complicates its
study. Known as the ‘‘vascular theory of late life depres-
sion,’’ some studies find that the risk of depression in
older adults without stroke increases as the number of
cerebrovascular risk factors increases, presumably sug-
gesting that depression is related to clinically silent,
small-vessel cerebrovascular disease.25 However, in at
least one study the relationship between vascular risk
factors and depression was not seen in older adults who
had a history of stroke.26 Further dissecting this complex
issue will require longitudinal cohorts in which depres-
sion symptoms, vascular risk factors, and vascular out-
comes are all well described.27
Depression symptoms have been linked not to
just increased stroke risk but also increased stroke
mortality. Analysis of more than 11,000 subjects in the
Multiple Risk Factor Interventions Trial (MRFIT)
cohort showed that depression symptoms were inde-
pendently associated with all-cause mortality and cardi-
ovascular disease mortality during 18 years of follow-
up.28 Importantly, the increased cardiovascular mortality
was due to increased stroke mortality (hazard ratio 2.0)
but not to increased coronary heart disease mortality.
Further support of this relationship was the observation
of a linear trend between depression symptoms and
Table 2 Depression as a Stroke Risk Factor
Study n Depression Assessment RR of Stroke (95% CI)
Ostir et al20 2478 CES-D 1.04 (1.01–1.09) for each 1-point increase on the CES-D
Jonas et al22 6095 Self-report (NHANES interview) 1.73 (1.30–2.31)
Ohira et al23 901 Zung SDS 1.9 (1.1–3.5) for total stroke, 2.7 (1.2–6.0) for ischemic
stroke
Nilsson et al24 Hospitalization for depression 1.22 (1.06–1.41)
Everson et al29 6676 Human Population Laboratory Depression scale 1.54 (1.06–2.22) for stroke mortality
CES-D, Centers for Epidemiologic Study–Depression scale; Zung SDS, Zung Self-rating Depression Scale.





















































mortality, where mortality risk increased as depression
symptoms increased. Another prospective cohort study
with 29 years of follow-up data also showed that report-
ing five or more depression symptoms at baseline was
associated with a 66% relative increase in stroke mortal-
ity, even when other stroke risk factors and change in
depression status and other risk factors over time were




Along with these intriguing epidemiological studies,
other interesting pathophysiological data are also emerg-
ing related to possible mechanisms of the increased
vascular risk in patients with depression. Possible vas-
cular-specific mechanisms linking depressive symptoms
and increased vascular risk include serotonin-mediated
effects on platelets and increased inflammation (inter-
leukin [IL]-6 and IL-1 b influence depression risk and
also stroke risk, possibly via enhanced atherosclerosis). It
is not yet clear, however, whether these mechanisms are
also related to added vascular risk in patients with PSD.
Surface expression of platelet glycoprotein GPIb has
been shown to be reduced in stroke patients and in those
with depression alone, compared with healthy controls,
but no additional reduction was observed in those with
both stroke and depression. These data suggest that
platelet dysfunction may possibly underlie the observed
relationship between depression and increased vascular
risk.30 Another study found that the number of platelet
serotonin transporters was low in stroke patients com-
pared with controls, which could theoretically lead to
increased platelet aggregation and elevated risk of
vascular events.31 Interestingly, the number of platelet
serotonin transporters was not associated with the devel-
opment of PSD. A possible genetic link between in-
creased risk of depression and increased vascular events
has also recently been proposed.32 This theory suggests
that the serotonin gene functional polymorphism may be
linked both to increased risk of depression and increased
risk of vascular events. Other lines of evidence in this
potential relationship come from treatment trials. One
study found that in patients with depression after MI,
selective serotonin reuptake inhibitor (SSRI) treatment
was associated with decreased platelet activation, even in
those patients already taking an antiplatelet medication,
suggesting a potential mechanism for a reduction in
cardiovascular events in depressed patients treated with
SSRIs after MI.33 Another interesting supporting piece
of evidence for this mechanism in MI patients is the
observation that cognitive behavioral therapy improved
depression in post-MI patients but did not reduce
subsequent cardiac events, while antidepressant treat-
ment was associated with significantly lower mortality or
nonfatal myocardial infarction.34 Further studies in this
area should help clarify whether depression-related dis-
ruptions in serotonin and subsequent platelet effects are
at least partially related to the relationship between
depression and vascular events.
In addition to platelet effects, behavioral factors
such as impaired self-management, limited physical
activity, impaired social roles and relationships, less
collaborative care with providers, and decreased compli-
ance also likely underlie the relationship between de-
pression and vascular disease and may account for the
worse outcomes seen in patients with depression in
combination with many other medical conditions.35–39
For example, a longitudinal study of Hispanic subjects
found that depressive symptoms were synergistic with
diabetes and associated with worse diabetes control
and increased micro- and macrovascular complications,
even when controlling for multiple sociodemographic
characteristics.35
Another possible mechanism linking depression
and vascular disease is that depressive symptoms may
influence the development of other vascular risk factors.
Data from the NHANES I Epidemiology Follow-up
Study demonstrated in up to 22 years of follow-up that
negative affect at baseline was associated with the
development of hypertension over time, even when
adjusting for baseline blood pressure and other demo-
graphic and vascular risk factors.40 This relationship has
been observed in other prospective cohort studies of
young adults as well.41
PSD EPIDEMIOLOGY
Although methodological differences in study cohorts
and methods of depression detection make pooling study
results difficult, cumulative evidence indicates that 25 to
40% of stroke patients suffer from PSD, equally divided
between major depression and other depressive disor-
ders.42–54 Importantly, these data come from both prac-
tice-based cohorts and population-based studies
(Table 3). Foundational work in PSD was done in the
1980s by Robinson and colleagues.50,51,53 Among their
many important contributions were the findings that:
(1) the prevalence of DSM-based diagnosis of PSD is
at least 30%, (2) PSD usually develops soon after stroke,
(3) PSD usually persists throughout the first 6 to
12 months poststroke and often up to 2 years, and (4)
PSD is associated with less neurological recovery after
stroke. A limitation of this work is the select nature of
the population (predominantly hospitalized African-
American males). Further, this study was conducted in
the early 1980s, before the widespread availability of
SSRI and other less toxic antidepressants, and few of the
patients with PSD received treatment. Several commun-
ity-based serial studies have also demonstrated that PSD
is frequent, persistent, and undertreated.42–45,47,49,52,54





















































A multicenter study in Italy demonstrated DSM-based
depression diagnoses in 34% of stroke survivors.54 The
Helsinki Stroke Memory Aging Study52 reported a
prevalence of 40% for any depressive disorder and 26%
for major depression at 3 to 4 months post–ischemic
stroke; 39% were receiving antidepressant therapy.
The FINNSTROKE Study49 evaluated 321 patients at
3 months poststroke and 311 patients at 12 months and
found a depression prevalence of 47% at both time
points. Only 17% were undergoing antidepressant drug
therapy at 12 months. The Sunnybrook Stroke Study47
evaluated 150 patients at 3 months and 136 at 12 months
and found a prevalence of ‘‘marked depressive symp-
toms’’ of 27% and 22% at these two time points. Fewer
than 25% of depressed patients received antidepressants,
and 70% of those depressed at 3 months remained so at
1 year. The Perth Community Stroke Study44 evaluated
294 patients at 4 months poststroke and found a PSD
prevalence of 23%. There were no differences between
first-ever and recurrent strokes. At 12 months post-
stroke, 59% of the men and 30% of the women were
still depressed. For those studies that identified major
and minor depression it was not apparent that the
prognosis differed by type of depressive disorder. The
hospital-based studies typically report a higher preva-
lence of PSD (40% or greater), whereas the community-
based studies report prevalences of 20 to 40%. By not
assessing patients until 3 to 4 months poststroke, how-
ever, most of these community-based studies were not
able to assess the prevalence and persistence of early-
onset depression and, in particular, its impact on func-
tional recovery and stroke-specific health-related quality
of life (HRQOL) during the critical months immedi-
ately poststroke.
PSD IMPACTS MANY HEALTH OUTCOMES
PSD is not only common but is also linked to worse
outcome in both patients and caregivers after ischemic
stroke. Just as depression in general has been associated
with poorer functional outcome in a variety of condi-
tions,58–63 PSD has similarly been linked to worse func-
tional outcome and increased mortality after stroke, even
when controlling for other variables. Specifically, de-
pressed patients have been found to have greater impair-
ments at various time points poststroke in activities of
daily living.58–63 This negative effect of PSD was present
even after depression remitted59 and was associated with
deterioration in function over time.58,60 Morris and
colleagues also demonstrated that patients with either
major or minor depression poststroke were 3.4 times
more likely to die during 10-year follow-up, and this risk
was even higher in those socially isolated.64 More
recently, data from a nationwide sample of veterans
with ischemic stroke who survived at least 30 days
poststroke showed that 3-year mortality was increased
25% in those with a new poststroke depression diagnosis
compared with those without depression.65 Finally,
there is growing evidence that PSD increases subsequent
health care utilization. This relationship has been shown
in other conditions,66–68 but a recent analysis of a na-
tional cohort of veterans with ischemic stroke showed
that those with depression (and to a lesser extent those
with other mental health conditions) poststroke had
greater utilization of outpatient health care services
and more inpatient admissions, even controlling for
other chronic conditions and when mental health out-
patient visits were omitted from the analyses.69
IMPACT ON STROKE CAREGIVERS
Family caregivers of stroke patients are impacted not
only by the stroke itself but also patient PSD. Stroke
caregivers in general have higher rates of depression,70–74
more physical symptoms,70,74 and higher levels of
emotional distress70,72–74 than caregivers of nonstroke
patients. Caregivers of patients with PSD may also be
more likely to be depressed themselves.73 Other factors
Table 3 Summary of PSD Prevalence Estimates
Study n Depression Assessment Time Poststroke Prevalence
Andersen et al42 285 HDRS 1 year 41%
Astrom et al43 80 DSM-III 3 years 16% (12 months); 31% (3 months)
Burvill et al44 294 DSM-III 4 months 23%
Fuh et al45 45 GDS Variable 62% (compared with 33% of 1,471 nonstroke
subjects)
Herman et al47 150 MADRS and Zung SDS 1 year 22–27% (3 months); 21–22% (1 year)
Kotila et al49 423 BDI 1 year 47% (3 months); 47% (1 year)
Robinson et al50 103 DSM-III 6 months 47%
Pohjasvaara et al52 277 DSM-III-R 4 months 40%
Toso et al54 1064 BDI, MADRS, DSM-IV 6 months 34%
HDRS, Hamilton Depression Rating Scale; DSM, Diagnostic and Statistical Manual; GDS, Geriatric Depression Scale; MADRS, Montgomery-
Asberg Depression Rating Scale; Zung SDS, Zung Self-rating Depression Scale; BDI, Beck Depression Inventory.





















































that may influence caregiver strain include amount of
time spent helping the patient and caregiver health
status.75,76 Caregivers of aphasic patients may be espe-
cially likely to experience greater distress and report
higher burden.77 The importance of understanding the
complex relationships between caregiver and patient
outcomes is increasingly realized,78,79 as family care-
givers play a large role in patient self-management of
chronic conditions and in symptom recognition and
compliance with treatment.
RISK FACTORS FOR DEVELOPING PSD
Many reports have addressed the question of what
specific factors are related to the development of PSD.
As with other studies of PSD, the generalizability of
these studies are often hampered by selection bias,
method of detecting depression, and time frame of
assessment. Nonetheless, some reasonably consistent
factors emerge as likely risk factors for the development
of PSD.
Lesion Location
One of the most studied and debated issues in the field of
stroke and depression research is whether specific stroke
locations are associated with increased risk of developing
depression. This possible explanation for the develop-
ment of PSD has been attractive to neuroanatomists and
neurophysiologists, because theoretically PSD might be
more likely to develop after lesions that disrupt central
nervous system (CNS) serotonin or norepinephrine
pathways. In various analyses, Robinson and colleagues
found that left hemisphere lesions, lesions in the right
basal ganglia, and lesions closer to the frontal pole were
associated with increased risk of developing PSD.80,81
Another study reported that lesions affecting the pal-
lidum were associated with an increased risk of depres-
sion diagnosis 3 months after stroke and that lesion size
was also associated with depression risk.82 Although a
well-conducted systematic review of the existing liter-
ature did not support the association between any
specific lesion location and the development of PSD83
and population-based studies have generally not found
an association between lesion location and PSD, another
meta-analysis by Narushima and colleagues did sup-
port the relationship of proximity to the frontal pole
and PSD risk.84 One of the difficulties in studying this
area, and specifically in conducting meta-analyses, is that
a large proportion of the articles on this topic come from
overlapping cohorts studied by Robinson and colleagues
and thus do not represent independent findings in
distinct stroke patients. As new neuroimaging techni-
ques emerge, this issue and the issue of whether lesion
location is related to treatment response will likely
continue to be studied and debated but, at present, lesion
location should not be used as a variable to determine
which stroke patients should be screened for PSD.
Stroke Severity
Many studies have examined the issue of whether
persons with more severe stroke are more likely to
develop PSD. This can be a complicated issue to exam-
ine because these patients are also more likely to have
communication and/or cognitive effects of stroke that
make depression assessment difficult and because the
relationship between stroke severity and depression may
be somewhat bidirectional. Stroke survivors with more
severe stroke impairments may be more likely to develop
depression, but there is also strong evidence that depres-
sion after stroke negatively impacts recovery, so cross-
sectional studies that do not take into account stroke
deficits at the time of stroke onset may reveal only a part
of this relationship.
Although the precise relationship may not always
be determined and some studies do not report this
association,85,86 multiple studies have found that in-
creased stroke impairment and/or functional dependence
are related to PSD at various time points.87–89 Both
Robinson and colleagues90 and Astrom and associates43
reported that the relationship between depression and
poststroke impairment is dynamic: the strength of their
association increased during the first 6 months post-
stroke and then decreased. Robinson has speculated that
reasons for this time-dependent relationship may in-
clude: (1) the most impaired patients either are more
likely to remain depressed or have worsened depression
symptoms over time, (2) depressed patients may have
less recovery in function, or (3) other factors influence
both depression and impairments/functional recovery
poststroke.91
Other PSD Risk Factors
Many other factors have also been reported to be
associated with increased risk of developing PSD,
although again the temporal relationship of these vari-
ables is not always clearly evaluated. In addition to lesion
location, factors purported to increase risk of developing
PSD include: female gender, increasing age, lack of
social support, cognitive dysfunction, and prestroke
history of depression. One literature synthesis has sug-
gested that the factors most consistently associated
with PSD are past history of depression, past personal
psychiatric history, dysphasia, functional impairments,
living alone, and poststroke social isolation.92 Differ-
ences in study cohorts and measurement of key variables
make it difficult to draw widely generalizable conclusions
from these data, and so screening of all patients regard-
less of PSD risk factors seems most appropriate from a
clinical standpoint.





















































SUICIDALITY IN PATIENTS WITH PSD
Because the incidence of successful suicide increases with
age, it is important to address the issue of suicidality
in stroke survivors. Several reports suggest that suicide
rates are increased in stroke survivors, with at least two
of these being well-designed population-based cohorts
in Denmark in which the risk of suicide was almost twice
as high in stroke patients compared with other age-
matched persons without stroke.93,94 Factors in addition
to depression symptoms that may be related to this risk
include prior history of stroke and increased disability.95
Many more patients likely have suicidal ideation but do
not act on these thoughts: one study reported that 7%
of adults with acute medical illnesses (including stroke)
had clinically significant suicidal ideation during up
to 24 months after the acute event.96 In our National
Institutes of Health (NIH)-funded case management
trial in PSD patients, we found that 10% of stroke
survivors endorse ‘‘thoughts of death or harming yourself’’
(itemnine from thePHQ-9), butwith standardized probe
questions, almost all of these represent passive thoughts
of death rather than active suicidal ideation (unpublished
data).Nonetheless, given the persistent reports of elevated
suicide risk in population-based cohorts, these data are
another piece of evidence supporting the routine screening
for depression in all stroke survivors.
TREATMENT OF DEPRESSION
IN STROKE SURVIVORS
Despite the long and extensive history of investigation
into the epidemiology and consequences of PSD, sur-
prisingly few well-conducted studies have been done of
sufficient size to address critical PSD treatment ques-
tions. In general, studies of PSD treatment can be
divided into two themes: antidepressants to prevent
PSD and antidepressants as treatment of PSD. Recently,
Cochrane reviews of antidepressant treatment have been
completed for both of these key questions.97,98 Although
both of these reviews conclude that evidence is insuffi-
cient to recommend treatment specifically for preventing
or treating depression in stroke patients, it would seem
overly simplistic and nihilistic to therefore conclude that
depression in patients who have had a stroke should
therefore remain untreated. This is especially the case as
the majority of PSD treatment studies that have been
conducted have been small, many have not used rigorous
clinical trial methodology, and most trials have demon-
strated reduction of depression symptoms in patients on
treatment, if not complete remission of depression.
Rather, the overwhelming evidence for treating depres-
sion, regardless of what other medical conditions coexist,
should at present be sufficient for providers to confi-
dently treat depression symptoms in stroke patients.
Future trials, like our ongoing National Institute for
Neurologic Disorders and Stroke (NINDS)-funded
study of depression case management versus usual care
in patients with PSD, will help inform this issue.
To provide help with interpreting the PSD treat-
ment literature, Table 4 details published randomized,
blinded, trials of PSD treatment.99–106 The majority of
these studies have tested SSRIs, but a few have used
other classes of antidepressant medications. Some trials
included only ischemic stroke patients but others in-
cluded those with hemorrhagic stroke types as well. In
general, most studies have demonstrated significant
improvements in depression symptoms but not always
in complete remission of depression. Whether this re-
duction in symptoms is clinically meaningful to patients’
quality of life and whether treatment of depression
affects rate or trajectory of recovery remain important
unanswered questions.
Some studies have attempted to compare different
antidepressants, but the small sample size raises the
question of what difference the study would actually
be powered to see. One of these found that citalopram
and reboxetine had similar efficacy and low side effect
profiles, but that citalopram was more effective in
depression with anxiety and reboxetine was more effec-
tive in depression with psychomotor retardation.107
Another study reported that nortriptyline was superior
to fluoxetine in efficacy and side effect profile, but this
was a very small study with a complicated crossover
design and high dropout rate, so conclusions were based
on less than 20 participants in each study arm and are
thus difficult to interpret.103
PREVENTING PSD
Relatively little evidence exists to suggest that treatment
of stroke patients to prevent the development of PSD is
beneficial, although strategies to address this hypothesis
in patients at especially high risk of developing PSD
have not been tested. One of the largest prevention trials
to date randomized 137 patients to treatment with
sertraline versus placebo for 12 weeks.108 Among treated
subjects, 13/70 developed depression by the end of the
treatment period, compared with 20/67 in the control
group (P¼< 0.05). Another study randomized 100
stroke patients to the SSRI mianserin versus placebo
for 1 year after stroke regardless of depressive symp-
toms.109 Early treatment with antidepressants did not
prevent PSD, likely due to the high dropout rate (only
64 patients had 12-month outcome assessment) and
small sample size. Another small study did show sig-
nificant benefit for preventing depression, with 2 of 35
mirtazipine-treated patients developing depression com-
pared with 14 of 35 control patients (P¼< 0.05).110
Finally, a small randomized, placebo-controlled trial of
fluoxetine 20 mg within 2 weeks of stroke onset did not
reduce depression symptoms compared with placebo at
4 weeks but was associated with reduced depression





















































symptoms at 12 weeks and 18 months. This suggested a
relatively high rate of spontaneous remission of early
depression symptoms, but also demonstrates potential
intermediate and long-term benefit of antidepressant
treatment in patients with depression after stroke.111
Regardless of whether they are used for preven-
tion or treatment of PSD, even less is known about other
classes of medications and nonpharmacological depres-
sion treatments, including psychostimulants,112,113 tri-
cyclic antidepressants,114,115 and buspirone.116 Other
studies have included short-term non–placebo-
controlled trials117 or open trials of antidepressants
and placebo.118,119 There are even fewer studies of non-
pharmacological treatments, like psychotherapy120 or
electroconvulsive therapy, for PSD.121 However, two
recent studies suggest a possible role for nonpharmaco-
logical treatments in reducing anxiety poststroke. In one
of these, a supportive program (three telephone calls and
one home visit) after stroke did not reduce depression
symptoms at 6 months poststroke compared with usual
care, but did reduce anxiety and improve subjects’ SF-36
Role-Emotional scores.122 Another study reported that
an educational program reduced patient anxiety (not
depression) at 6 months compared with usual care.123
Further studies of this type, employing proven depres-
sion treatments like cognitive behavioral therapy and
using proven delivery models like telephone-based coun-
seling and collaborative care, should be undertaken in
stroke survivors.124
Not surprisingly, in light of the relatively meager
amount of high-quality treatment evidence, many im-
portant questions remain unanswered. Although the
notion that PSD is undertreated is generally supported
by the community-based studies and by surveys in the
United States, undertreatment of PSD was not found in
a recent Swedish national survey.125 In this self-report
survey, 14% of stroke survivors had depressive symptoms
and 25% of those with stroke were taking an antide-
pressant. However, 8% of those reporting depressive
symptoms were not treated. Stroke survivors were sig-
nificantly more likely to be taking an antidepressant
than those without stroke. As antidepressant use has
become more convenient and better accepted culturally,
and medications with less side effects have become
available, it may be that more patients will be treated.
Conversely, recent negative press about antidepressants,
particularly SSRIs, and suicide risk in children may
reduce providers’ willingness to treat and patients’ ac-
ceptance of treatment.
Another critical question that is still largely un-
answered is whether treatment of PSD reduces mortality
risk. One study that has shed some light on this is
Table 4 Randomized, Placebo-Controlled Clinical Trials of Antidepressants for Treatment of PSD
Study Drug, Duration Drug vs Placebo Results
Lipsey et al99 Nortriptyline, 6 weeks 17 vs 22 HAM-D improved 11.5 points (14 to 2.5) in drug
group vs 7 (16.5 to 9.5) in placebo group (P¼ 0.0006)
Zung depression score improved 18 vs 12 points (P¼ 0.03)
Reding et al100 Trazodone, 4 weeks 27 total Randomized 27 admitted inpatients in stroke rehabilitation to
trazodone vs placebo, whether or not they were depressed
Improved Zung scores in the subgroup of 16 patients who had
a positive DST
Andersen et al102 Citalopram, 6 weeks 33 vs 33 HAM-D improved 8 (19.4 to 11.4) in drug group vs 4.8 (18.9 to
14.1) in placebo group (P <0.05)
In the 59 completers, HAM-D more likely to fall  50% in drug
than in placebo group (59% vs 28%, P < 0.05)
Fruehwald et al106 Fluoxetine, 12 weeks 26 vs 24 HAM-D improved in 8 of treatment group compared with 6 of
placebo group (P > 0.05)
Murray et al105 Sertraline, 26 weeks 62 vs 61 31 in treatment group compared with 34 in placebo group
(P > 0.05)
Wiart et al104 Fluoxetine, 6 weeks 16 vs 15 MADRS decreased in 16.7 in treatment group compared with
8.5 in placebo group (P <0.05)
Ohtomo et al101 Aniracetam, 12 weeks 108 vs 65 Clinician impression of no depression at end of treatment in 52
of treatment group compared with 32 in placebo group
(P > 0.05)
Robinson et al103 Fluoxetine, nortriptyline,
12 weeks
23 vs 16 vs 17 Successful treatment in 10/16 nortriptyline, 2/23 fluoxetine,
and 4/17 placebo patients
Significantly lower HAM-D scores in nortriptyline group (9.0)
and placebo group (12.2) than fluoxetine group (18.5)
HAM-D, Hamilton Depression Inventory; MADRS, Montgomery-Asberg Depression Rating Scale.





















































the trial of fluoxetine, nortriptyline, and placebo for
12 weeks in the first 6 months poststroke.126 During
9 years of follow-up, those patients who completed the
full dose of antidepressant therapy (n¼ 53) had signifi-
cantly lower mortality than those receiving placebo for
12 weeks (n¼ 28). However, the relatively high number
of ‘‘noncompleters’’ (n¼ 23) and their relationship to the
analysis in this report make it somewhat difficult to draw
firm conclusions regarding the data. For example, per-
haps other unmeasured characteristics that differed be-
tween completers and noncompleters in the study are
associated with subsequent mortality risk. Other ques-
tions that need further study include: (1) Does the
improvement in depression symptoms translate to re-
mission of depression diagnosis and to improved quality
of life in stroke survivors? (2) Do early symptoms of PSD
(i.e., in the first 1 to 2 months) need to be treated, or
does PSD during this time period often spontaneously
improve? (3) Does treatment of PSD influence stroke
recovery? (4) If patients are not depressed soon after
stroke, how likely are they to become depressed later? (5)
Do symptoms of emotionality immediately after stroke
predict the likelihood of subsequent depression? One
recent small study suggested that the early initiation of
antidepressants in patients with PSD may be important.
In this study (n¼ 62), those who received antidepressant
treatment within 1 month poststroke had less functional
impairment at 3 months and at 2 years poststroke




Although neurologists may or may not elect to manage
depression in their patients, in some patients with
chronic progressive neurological disease the neurologist
may in effect be a primary care provider. Thus, knowing
the current best practices in depression assessment,
treatment, and care delivery in primary care may be
beneficial. Stroke patients have complicated post–acute
outpatient needs, including review of diagnostic tests,
adjustment of medications to treat stroke risk factors,
assessment of rehabilitation needs, and symptom
management. These competing patient and provider
demands can make depression detection difficult. In
some managed care settings, including the Veterans
Health Administration (VHA), annual depression
screening for all patients in primary care is a performance
measure. Because almost one third of patients screen
positive for depression at their first neurology clinic visit,
neurologists may also want to adopt a brief, self-com-
pleted depression screening tool like the PHQ-9 in their
outpatient clinic materials.128 In addition to initiating an
antidepressant, key components of quality depression
care include a follow-up visit within 6 weeks of initial
diagnosis and maintenance of antidepressant therapy for
at least 6 months. One care model that can help ensure
adequate follow-up and promote adherence to medica-
tion management is telephone-based psychotherapy and
care management.124,129 At the very least, neurologists
should consider screening all stroke patients for depres-
sion in the first few months poststroke, and then either
initiating treatment or ensuring prompt communication
with primary care providers to initiate and monitor
treatment.
FUTURE DIRECTIONS/CONCLUSION
Much work remains to be done to better understand
the reasons why stroke survivors develop depression, to
predict what treatments are most likely to be efficacious
in ameliorating or preventing depression, and to under-
stand how depression influences stroke recovery across
the spectrum of behavioral, anatomical, chemical, and
genetic mediators. Likewise, much work also remains to
be done to ensure that patients and providers recognize
the symptoms of depression after stroke and that patients
receive and accept best practices in treating depression.
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